Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log

August 24, 2024

Renamed

• Antihypertensive drug renamed to Antihypertensive.
• Draft:JJC8-088 renamed to JJC8-088.
• Modafiendz renamed to Modafiendz.
• Draft:RDS03-94 renamed to RDS03-94.

Reassessed

• Lobeline (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t) Importance rating changed from Unknown-Class to Low-Class. (rev · t)

Assessed

• AZD2327 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
• Antihypertensive (talk) assessed. Quality assessed as B-Class. (rev · t) Importance assessed as Top-Class. (rev · t)
• List of Lambda Kappa Sigma chapters (talk) assessed. Quality assessed as List-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
• Draft:Pranas Šimanauskas (talk) assessed. Importance assessed as NA-Class. (rev · t)

August 23, 2024

Renamed

• Draft:LSN2463359 renamed to LSN2463359.
• SR-95103 renamed to Famiraprinium.

Assessed

• Famiraprinium (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• L-701324 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Ondelopran (talk) assessed. Quality assessed as NA-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

August 22, 2024

Renamed

• CRL-40,940 renamed to Flmodafinil.
• CRL-40,941 renamed to Fladrafinil.

Assessed

• Fladrafinil (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Flmodafinil (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Lazertinib (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)

August 20, 2024

Reassessed

• 3-Hydroxyaspartic acid (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Gamma-Hydroxybutyraldehyde (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Inosine pranobex (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
• PDE4 inhibitor (talk) reassessed. Quality rating changed from Redirect-Class to Start-Class. (rev · t) Importance rating changed from NA-Class to Unknown-Class. (rev · t)

Assessed

• (2R,3R)-Hydroxybupropion (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Cyclic adenosine-inosine monophosphate (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

August 19, 2024

Renamed

• Transgender hormone therapy renamed to Gender-affirming hormone therapy.

Reassessed

• Desmethylzopiclone (talk) reassessed. Quality rating changed from Unassessed-Class to Start-Class. (rev · t) Importance rating changed from Unknown-Class to Low-Class. (rev · t)

Assessed

• ADL-5859 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
• Beta Phi Sigma (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
• Gender-affirming hormone therapy (talk) assessed. Quality assessed as B-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
• Draft:JJC8-088 (talk) assessed. Importance assessed as NA-Class. (rev · t)
• Draft:LSN2463359 (talk) assessed. Importance assessed as NA-Class. (rev · t)
• Draft:Modafiendz (talk) assessed. Importance assessed as NA-Class. (rev · t)
• Draft:RDS03-94 (talk) assessed. Importance assessed as NA-Class. (rev · t)
• ZD-9379 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)

August 18, 2024

Renamed

• Draft:Desmethylzopiclone renamed to Desmethylzopiclone.
• Draft:RTI-5152-12 renamed to RTI-5152-12.

Reassessed

• Adewusi Michael Olufemi (talk) reassessed. Quality rating changed from Unassessed-Class to Redirect-Class. (rev · t) Importance rating changed from Unknown-Class to NA-Class. (rev · t)
• Catherine M. Cahill (talk) reassessed. Quality rating changed from Unassessed-Class to Stub-Class. (rev · t)
• Monoaminergic activity enhancer (talk) reassessed. Quality rating changed from Unassessed-Class to B-Class. (rev · t)

Assessed

• CGP-39551 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• EF-1502 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Template:Monoaminergic activity enhancers (talk) assessed. Quality assessed as Template-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
• ORG-24598 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• SR-95103 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• VU-0152100 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Virapinib (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)